Evercore ISI Group Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $50
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Evercore ISI Group analyst Cory Kasimov initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $50.
Evercore ISI Group analyst Cory Kasimov initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $50.